PainReform Advances OcuRing-K Phase 2 Trial for Drop-Free Post-Cataract Surgery Pain Management
Key Insights
PainReform has launched its development plan for OcuRing-K (search), a bioerodible sustained-release implant that delivers ketorolac directly into the eye during cataract (search) surgery to prevent post-operative pain and inflammation (search).
The technology addresses major limitations of traditional eye drop regimens by providing consistent therapeutic levels with significantly lower total drug exposure than standard treatments.
Preclinical studies and Phase I clinical evaluation demonstrated reductions in post-surgical pain and inflammation (search) while using markedly lower drug exposure compared to conventional eye-drop regimens.
PainReform Ltd. has announced the commencement of its development plan for OcuRing-K (search), a novel sustained-release ocular therapy designed to eliminate the need for post-operative eye drops following cataract (search) surgery. The company is now progressing toward a Phase 2 clinical trial for the innovative drop-free treatment approach.
Revolutionary Drop-Free Technology
OcuRing-K (search) represents a paradigm shift in post-cataract (search) surgery care through its bioerodible sustained-release implant technology. The device is applied to the haptic of an intraocular lens (IOL) during cataract surgery and continuously releases ketorolac, an anti-inflammatory and analgesic drug, directly into the eye. This approach is designed to provide extended and consistent intraocular therapeutic levels of the NSAID (non-steroidal, non-opiate, anti-inflammatory analgesic) without requiring patient-administered drops.
The technology addresses critical limitations of traditional postoperative eye-drop regimens, which typically require multiple daily steroid and NSAID drops for several weeks but deliver only a small fraction—often less than 5%—of the drug inside the eye. This inefficient delivery produces sharp fluctuations in drug levels, increasing the potential for inconsistent efficacy and side effects.
Clinical Evidence and Safety Profile
Preclinical studies and a Phase I clinical evaluation demonstrated significant advantages over conventional treatments. The studies showed reductions in post-surgical pain and inflammation (search) while using significantly lower total drug exposure than standard eye-drop regimens. The sustained-release kinetics of OcuRing-K (search) maintained therapeutic levels over time, supporting the potential for improved ocular safety, reduced systemic side effects associated with high-volume topical dosing, and enhanced patient compliance, particularly among elderly populations.
OcuRing-K (search)'s in-situ depot formulation provides direct, localized delivery to target tissues with markedly lower systemic exposure, offering controlled and stable therapeutic coverage compared to conventional eye drops. By removing the need for patient-administered drops, the technology also reduces contamination risks, such as inadvertent contact between dropper bottles and ocular tissues.
Addressing a Massive Market Need
Cataract (search) surgery represents one of the most common procedures worldwide, with approximately 4.5 million surgeries performed annually in the United States and more than $9 billion in global annual surgical procedure volume. Current postoperative management depends heavily on multi-week corticosteroid and NSAID eye-drop regimens—treatments that are burdensome for elderly patients and often delivered inconsistently to ocular tissues.
Traditional eye drop regimens are associated with several significant drawbacks, including poor compliance, particularly among elderly patients; inconsistent and inefficient drug delivery; and risks associated with steroids, including elevated intraocular pressure and potential for infection and contamination.
Strategic Development Path
Following PainReform's majority investment in LayerBio (search), the company conducted a methodical internal assessment with LayerBio's management team to define development priorities and establish a clear path for advancing the program. The development plan identifies post-cataract (search) pain and inflammation (search) as the initial target indication for OcuRing-K (search).
"Commencing the development plan for OcuRing-K (search) and advancing work toward the next clinical trial marks a key milestone in our strategy to deliver meaningful, drop-less solutions to one of the most common and impactful surgical procedures worldwide," said Ehud Geller, Chairman of PainReform. "LayerBio (search)'s data demonstrate the potential of this sustained-release depot technology to provide consistent pain and inflammation (search) control with significantly lower drug exposure than traditional drops."
Platform Technology with Broader Applications
LayerBio (search)'s sustained-release platform supports delivery of a wide range of other ocular therapeutics—including NSAIDs, antibiotics, steroids, and anti-VEGF agents—aligning with PainReform's plans to explore additional ophthalmic indications following the development of OcuRing-K (search). This versatility positions the technology as a potential solution for multiple ocular conditions beyond post-cataract (search) surgery care.
The program continues to be led by Dr. Ken Mandell, LayerBio (search)'s founder and Chief Executive Officer, a Harvard-trained ophthalmologist and biotechnology innovator with more than a dozen INDs and multiple Phase 1-3 ophthalmic trials to his credit.
PainReform and LayerBio (search) plan to advance OcuRing-K (search) through its next stage of clinical development in the United States, where approval could unlock a high-volume reimbursable market and enable expansion across additional ophthalmic indications.